Sociedad Americana de Hirudoterapia

Effect of O-glycosylation and tyrosine sulfation of leech-derived peptides on binding and inhibitory activity against thrombin

Basic science published in Chem Commun (2011)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDesarrollo de fármacosFarmacología salivalHsieh YS et al. · Chemical communications, 2011

Abstract

Synthesis of sulfated and unsulfated (glyco)peptide fragments of Hirudin P6 (a potent anticoagulant from the leech Hirudinaria manillensis) is described. The effect of O-glycosylation and tyrosine sulfation on thrombin binding and peptidolytic activity was investigated, together with the inhibition of fibrinogen cleavage.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsBinding SitesGlycosylationMolecular ConformationPeptidesStructure-Activity RelationshipThrombinTyrosine

Resumen

Synthesized sulfated and glycosylated Hirudin P6 fragment peptides show tyrosine sulfation enhances thrombin binding.

Por qué esto importa para la hirudoterapia

This study synthesized sulfated and unsulfated (glyco)peptide fragments of Hirudin P6—a potent anticoagulant from the leech Hirudinaria manillensis—and examined the effect of O-glycosylation and tyrosine sulfation on thrombin binding, peptidolytic activity, and inhibition of fibrinogen cleavage. This is relevant to ASH because it clarifies structure–activity relationships of a leech-derived thrombin inhibitor, informing how post-translational modifications modulate anticoagulant potency. The caveat is that this is an in-vitro biochemical/synthetic peptide study with no whole leech, no secretome, and no clinical or animal data, so relevance to actual hirudotherapy is indirect and mechanistic only.

Citación

Effect of O-glycosylation and tyrosine sulfation of leech-derived peptides on binding and inhibitory activity against thrombin.

Hsieh YS et al. · Chemical communications, 2011

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsSalivary Gland SecretionAnti-Inflammatory MechanismsSalivary ComplexHirudinAnticoagulation CompoundsHemostasisOtolaryngologyPost-Thrombotic Syndrome

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.